-
公开(公告)号：KR101275258B1
公开(公告)日：2013-06-17
申请号：KR1020110057664
申请日：2011-06-14
Applicant: 한올바이오파마주식회사
IPC: A61K31/155 , A61K31/70 , A61P3/10 , A61P35/00
CPC classification number: A61K31/7004 , A61K9/2031 , A61K9/2054 , A61K9/209 , A61K9/2866 , A61K9/4866 , A61K9/5084 , A61K31/155 , A61K31/506 , A61K45/06 , A61K2300/00
Abstract: 본 발명은 펜포르민 또는 그의 약제학적으로 허용 가능한 염과, 2-데옥시-D-글루코스를 활성 성분으로 포함하고, 항암 활성을 나타내는 약제학적 조성물에 관한 것이다. 이러한 약제학적 조성물은 각 활성 성분들간의 상승 작용을 통해 각각의 단일 활성 성분만을 사용하였을 경우에 비하여 훨씬 우수한 항암 효과를 나타냄과 동시에, 투여량이 감소되어 약물에 따른 부작용을 감소시킬 수 있다. 또한, 본 발명은 활성성분의 시간차 방출 또는 시간차 투여를 통해 펜포르민에 의한 유산산증과 같은 부작용을 현저히 감소시킬 수 있다. 특히 본 발명에 따른 약제학적 조성물은 환자의 복약 순응도 또한 상승하여, 각종 암을 치료하는데 매우 유용하게 사용될 수 있다.
-
公开(公告)号：KR101181172B1
公开(公告)日：2012-09-18
申请号：KR1020090014851
申请日：2009-02-23
Applicant: 한올바이오파마주식회사
Abstract: 본 발명은 활성성분으로 아토르바스타틴(Atorvastatin), 그의 이성질체 또는 그의 약학적으로 허용하는 염을 포함하는 선방출성 구획 및 약리학적 활성성분으로 암로디핀(Amlodipine), 그의 이성질체 또는 그의 약학적으로 허용하는 염을 표함하는 지연방출성 구획을 포함하는 약제학적 제제를 제공한다. 본 발명의 제제는 아토르바스타틴과 암로디핀의 용출속도를 달리 구성하여 약물 상호간의 길항 작용 및 부작용을 방지하고, 2종의 약물을 단회 투여함으로써 환자의 복용을 용이하게 하는 효과를 나타낸다.
암로디핀, 아토르바스타틴, 시간차 투여, 복합제제-
公开(公告)号：KR1020120065308A
公开(公告)日：2012-06-20
申请号：KR1020120059607
申请日：2012-06-04
Applicant: 한올바이오파마주식회사
IPC: C07C279/26 , C07C309/02 , A61K31/145 , A61P3/08
CPC classification number: C07C309/04 , C07C279/26
Abstract: PURPOSE: A pharmaceutical composition containing metformin methanesulfonate salt is provided to have an excellent AMPKα activity and to increase pharmaceutical and physical advantages including solubility, stability, and non-hygroscopic property. CONSTITUTION: A pharmaceutical composition contains metformin methanesulfonate as an active ingredient. The metformin methanesulfonate has a structure represented by chemical formula 1. A melting point of the metformin methanesulfonate is 194.0-194.5 deg. Celsius. A pharmaceutical composition is effective for preventing or treating diabetes, metabolic syndrome, diabetic complication, menstrual irregularity, hypertension, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome, cancer, muscle pain, rhabdomyolysis, and/or menopausal syndrome.
Abstract translation: 目的：提供含有二甲双胍甲磺酸盐的药物组合物以具有优异的AMPKα活性并增加药物和物理优点，包括溶解性，稳定性和非吸湿性。 构成：药物组合物含有作为活性成分的甲磺酸二甲双胍。 二甲双胍甲磺酸盐具有由化学式1表示的结构。甲磺酸二甲双胍的熔点为194.0-194.5℃。 摄氏度。 药物组合物可有效预防或治疗糖尿病，代谢综合征，糖尿病并发症，月经不规则，高血压，脂肪肝，冠状动脉疾病，骨质疏松症，多囊卵巢综合症，癌症，肌肉疼痛，横纹肌溶解症和/或绝经综合征。
-
44.发明公开Ｎ,Ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 无效N，N-二甲基咪唑偶氮二异丁酸丁酯，其制备方法，包含其的药物组合物和包括其的组合制剂
公开(公告)号：KR1020120032502A
公开(公告)日：2012-04-05
申请号：KR1020120016834
申请日：2012-02-20
Applicant: 한올바이오파마주식회사
IPC: C07C279/26 , C07C53/124 , A61K31/155 , A61P35/00
CPC classification number: A61K31/155 , C07C53/124 , C07C279/26
Abstract: PURPOSE: Metformin butyrate is provided to have excellent solubility, stability, non-hygroscopic, adhesion preventing property, processability as formulation, pharmacological effect, and to be manufactured under mild condition with high yield. CONSTITUTION: Metformin butyrate comprises a structure in chemical formula 1. The melting point of the crystal shape is 162 °C. A manufacturing method of the metformin in chemical formula 1 comprises a step of manufacturing metformin free base in chemical formula 3, by reacting metformin hydrochloride in chemical formula 2 with a base under organic solvent, and a step of reacting the metformin free base with butyl acid.
Abstract translation: 目的：提供二甲双胍丁酸酯具有优异的溶解性，稳定性，非吸湿性，防粘连性，作为制剂的加工性，药理作用，并以高产率在温和条件下制备。 构成：丁二酸二甲酯包括化学式1的结构。晶体形状的熔点为162℃。 化学式1中的二甲双胍的制造方法包括通过化学式2中的二甲双胍盐酸盐与有机溶剂中的碱反应制备化学式3中的二甲双胍游离碱的步骤，以及使二甲双胍游离碱与丁酸反应的步骤 。
-
公开(公告)号：KR1020110136753A
公开(公告)日：2011-12-21
申请号：KR1020110057664
申请日：2011-06-14
Applicant: 한올바이오파마주식회사
IPC: A61K31/155 , A61K31/70 , A61P3/10 , A61P35/00
CPC classification number: A61K31/7004 , A61K9/2031 , A61K9/2054 , A61K9/209 , A61K9/2866 , A61K9/4866 , A61K9/5084 , A61K31/155 , A61K31/506 , A61K45/06 , A61K2300/00
Abstract: PURPOSE: A pharmaceutical composition containing phenformin and 2-deoxy-D-glucose is provided to ensure excellent anticancer activity with reduced side effect. CONSTITUTION: A pharmaceutical composition for preventing or treating cancer contains phenformin pharmaceutically acceptable salt thereof and 2-deoxy-D-glucose. The pharmaceutically acceptable salt of phenformin is phenformin hydrochloride. The composition is an oral or parenteral type and additionally contains an anticancer agent as an active ingredient. The cancer is uterine cancer, breast cancer, gastric cancer, colorectal cancer, lung cancer, skin cancer, blood caner, or liver cancer.
Abstract translation: 目的：提供含有苯乙双胍和2-脱氧-D-葡萄糖的药物组合物，以确保优异的抗癌活性，减少副作用。 构成：用于预防或治疗癌症的药物组合物含有苯乙双胍药物上可接受的盐和2-脱氧-D-葡萄糖。 苯乙双胍的药学上可接受的盐是盐酸苯乙双胍。 组合物是口服或非肠道型，另外含有抗癌剂作为活性成分。 癌症是子宫癌，乳腺癌，胃癌，结肠直肠癌，肺癌，皮肤癌，血癌或肝癌。
-
Patent Agency Ranking
公开(公告)号：KR101043816B1
公开(公告)日：2011-06-22
申请号：KR1020080100245
申请日：2008-10-13
Applicant: 한올바이오파마주식회사
IPC: A61K9/22 , A61K31/155
Abstract: 본 발명은 메트포르민의 경구투여용 서방성 제제 및 이의 제조방법에 관한 것으로서, 더욱 상세하게는 메트포르민과 선택된 소수성 서방화 담체 및 팽윤성 고분자를 이용하여 서방정을 제조함으로써 상기 팽윤성 고분자의 수화로 인한 수팽창과 상기 소수성 고분자로 인한 수분 침투의 차단으로 약물 방출속도를 조절할 수 있도록 하였고, 유효성분인 메트포르민 또는 이의 염의 양에 비해 소량의 고분자를 사용하고도 메트포르민의 방출속도를 효과적으로 조절하여 일정한 혈중 농도를 유지시킬 수 있으면서도 크기가 작아 복용의 편리성이 개선된 메트포르민 경구투여용 서방성 제제 및 이의 제조방법에 관한 것이다.
메트포르민, 서방성 제제, 소수성 서방화 담체-
47.发明公开
公开(公告)号：KR1020110021693A
公开(公告)日：2011-03-04
申请号：KR1020100082555
申请日：2010-08-25
Applicant: 한올바이오파마주식회사
IPC: C07D307/32 , A61K31/341 , A61P3/10
CPC classification number: C07D307/62
Abstract: PURPOSE: A metformin ascorbate and a pharmaceutical composition containing the same are provided to ensure excellent stability and proceesibility of tablet. CONSTITUTION: A metformin ascorbate is denoted by chemical formula 1. The melting point of metformin ascorbate is 145 degree celsius. A pharmaceutical composition for preventing or treating diabetes, metabolic syndrome, diabetic complication, hypertension, fatty liver, or cancer contains metformin ascorbate of chemical formula 1 as an active ingredient. The composition is combined with a second drug, such as anti-cancer drug, anti-hypertension agent, or anti-obesity agent. The pharmaceutical composition is manufactured in the form of tablet, soft capsule, hard capsule, pill, granule, powder, injection, or liquid. The composition is sustained release or rapid release.
Abstract translation: 目的：提供二甲双胍抗坏血酸盐和含有它们的药物组合物，以确保片剂的优异稳定性和可操作性。 构成：二甲双胍抗坏血酸由化学式1表示。二甲双胍抗坏血酸的熔点为145摄氏度。 用于预防或治疗糖尿病，代谢综合征，糖尿病并发症，高血压，脂肪肝或癌症的药物组合物含有化学式1的二甲双胍抗坏血酸作为活性成分。 该组合物与第二种药物如抗癌药物，抗高血压剂或抗肥胖剂组合。 药物组合物以片剂，软胶囊，硬胶囊，丸剂，颗粒剂，粉剂，注射剂或液体的形式制备。 组合物持续释放或快速释放。
-
公开(公告)号：KR1020110021690A
公开(公告)日：2011-03-04
申请号：KR1020100082552
申请日：2010-08-25
Applicant: 한올바이오파마주식회사
IPC: C07C279/26 , C07C309/14 , A61K31/155 , A61P3/10
CPC classification number: A61K31/145 , A61K31/155 , C07C279/26 , C07C309/14
Abstract: PURPOSE: A metformin taurine salt is provided to ensure excellent stability, low toxicity, antioxidant activity and excellent AMPKa-activating effects, to enable easy tabletting, and thereby enabling use in treating glycosuria, diabetes, metabolic syndrome, and diabetes complications. CONSTITUTION: A metformin taurine salt is represented by chemical formula 1 and has a melting point of 134.1 °C. A pharmaceutical composition contains the metformin taurine salt as an active ingredient. The metformin taurate can be effectively used in treating glycosuria, diabetes, metabolic syndrome, diabetes complications, menstrual irregularities, hypertension, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome, cancer, myalgia, symptoms of muscle cell cytotoxicity, climacterium and rhabdomyolysis, etc., and provides antioxidant activity.
Abstract translation: 目的：提供二甲双胍牛磺酸盐，以确保优异的稳定性，低毒性，抗氧化活性和优异的AMPKa活化作用，使易于制片，从而可用于治疗糖尿病，糖尿病，代谢综合征和糖尿病并发症。 构成：二甲双胍牛磺酸盐由化学式1表示，熔点为134.1℃。 药物组合物含有二甲双胍牛磺酸盐作为活性成分。 二甲双胍牛磺酸可有效用于治疗糖尿病，糖尿病，代谢综合征，糖尿病并发症，月经不调，高血压，高脂血症，脂肪肝，冠状动脉疾病，骨质疏松症，多囊卵巢综合征，癌症，肌痛，肌肉细胞毒性症状， 和横纹肌溶解等，并提供抗氧化活性。
-
49.发明公开Ｎ,Ｎ―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 无效N，N-二甲基咪唑二恶烷二酸酯，其制备方法，包含其的药物组合物和包括其的组合制剂
公开(公告)号：KR1020110007984A
公开(公告)日：2011-01-25
申请号：KR1020100069243
申请日：2010-07-16
Applicant: 한올바이오파마주식회사
IPC: C07C279/26 , C07C277/00 , A61K31/155 , A61P3/10
CPC classification number: C07C53/122 , C07C277/00 , C07C279/26
Abstract: PURPOSE: A metformin propionate is provided to ensure an excellent pharmacological effect as compared with metformin hydrochloride and to achieve a therapeutic purpose by administering an amount less than metformin hydrochloride. CONSTITUTION: A metformin propionate is represented by chemical formula 1. A method for preparing the metformin propionate represented by chemical formula 1 comprises the steps of: reacting metformin hydrochloride represented by chemical formula 2 with base in an organic solvent to prepare metformin free base represented by chemical formula 3; and reacting the metformin free base with propionic acids.
Abstract translation: 目的：提供丙酸二甲双胍以确保与二甲双胍盐酸盐相比具有优异的药理作用，并通过施用少于二甲双胍盐酸盐的量来达到治疗目的。 构成：丙酸二甲双胍由化学式1表示。由化学式1表示的制备丙酸二甲双胍的方法包括以下步骤：将由化学式2表示的二甲双胍盐酸盐与碱在有机溶剂中反应，制备由 化学式3; 并使二甲双胍游离碱与丙酸反应。
-
公开(公告)号：KR1020100060595A
公开(公告)日：2010-06-07
申请号：KR1020080119245
申请日：2008-11-28
Applicant: 한올바이오파마주식회사
IPC: A61K9/24 , A61K31/455
CPC classification number: A61K9/2866 , A61K9/282 , A61K9/284 , A61K9/2893 , A61K31/455
Abstract: PURPOSE: A pulsatile release formulation and a method for manufacturing the same are provided to improve drug compliance by reducing administration number of the drug. CONSTITUTION: A pulsatile release formulation comprises: an inner immediate release compartment having nicorandil and stabilizing agent; a release suppression compartment surrounding the inner immediate release compartment without nicorandil; and an outer immediate compartment containing the nicorandil and stabilizing agent. The stabilizing agent is fumaric acid, oxalic acid, or stearyl fumaric acid sodium. A method for manufacturing the pulsatile release formulation comprises: a step of compartmenting; a step of preparing release suppression compartment; a step of suspending nicorandil and stabilizing agent in anhydrous ethanol.
Abstract translation: 目的：提供脉冲释放制剂及其制造方法，以通过减少药物的给药数量来改善药物依从性。 构成：脉动释放制剂包括：具有尼可地尔和稳定剂的内部快速释放隔室; 包围没有尼可地尔的内部快速释放隔室的释放抑制室; 和含有尼可地尔和稳定剂的外部立即隔室。 稳定剂是富马酸，草酸或富马酸硬脂酸钠。 制备脉冲释放制剂的方法包括：分隔步骤; 制备释放抑制室的步骤; 将尼可地尔和稳定剂悬浮在无水乙醇中的步骤。
-
-
-
-
-
-
-
-
-
Search Results
108
records
(took 0.034 seconds)
